Karlsborg M, Gram L, Dam M
Neurologisk afdeling, Hvidovre Hospital.
Ugeskr Laeger. 1996 Apr 1;158(14):1969-72.
The efficacy of treatment with lamotrigine (LTG) was evaluated in 92 patients with refractory epileptic seizures (46 women and 46 men aged 14-80 years, median 32 years). Seventy-one patients had partial epilepsy and 21 had primary generalized epilepsy. Patients were treated from zero to four (most frequently two) other antiepileptic drugs (AEDs). Maintenance dose of LTG was 50-800 mg daily (median 300 mg). Fifteen percent of the patients became seizure-free (13% of patients with partial epilepsy, 24% with primary generalized epilepsy). Thirty-eight percent of patients experienced at least 50% reduction in seizure frequency. Twenty-six percent of patients had a significant increase in seizure frequency (the same percentage in the two groups). Adverse events were recorded in 61% of patients, but most symptoms disappeared after dose reduction in concomitant AEDs. LTG was discontinued in 22% of patients, either because of adverse events or lack of effect. We conclude, that LTG is effective in reducing seizure frequency in patients with therapyresistant primary generalized epilepsy or partial epilepsy. Toxicity appears to be limited.
对92例难治性癫痫发作患者（46例女性和46例男性，年龄14 - 80岁，中位数32岁）评估了拉莫三嗪（LTG）的治疗效果。71例患者患有部分性癫痫，21例患有原发性全身性癫痫。患者接受过0至4种（最常见为2种）其他抗癫痫药物（AEDs）的治疗。LTG的维持剂量为每日50 - 800 mg（中位数300 mg）。15%的患者癫痫发作停止（部分性癫痫患者中为13%，原发性全身性癫痫患者中为24%）。38%的患者癫痫发作频率至少降低了50%。26%的患者癫痫发作频率显著增加（两组中的比例相同）。61%的患者记录到不良事件，但大多数症状在同时服用的AEDs剂量减少后消失。22%的患者因不良事件或无效而停用LTG。我们得出结论，LTG在降低耐药性原发性全身性癫痫或部分性癫痫患者的癫痫发作频率方面有效。毒性似乎有限。
